UK Guidance Document: Treatment of Metastatic Breast Cancer

Clinical Oncology

Volumn 24, Issue 3, 2012, Pages 169-176

  Coleman, R E ^a   Bertelli, G ^b   Beaumont, T ^c   Kunkler, I ^d   Miles, D ^e   Simmonds, P D ^f   Jones, A L ^g   Smith, I E ^h  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SINGLETON HOSPITAL   (United Kingdom)

^c Breast Cancer Care   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e MOUNT VERNON HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Advanced breast cancer; Multidisciplinary care; Treatment guidelines

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CARBOPLATIN; CORTICOSTEROID; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FULVESTRANT; GEMCITABINE; GOSERELIN; LAPATINIB; LETROZOLE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ANGIOGENESIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CARDIOTOXICITY; DRUG POTENTIATION; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE PLANNING; HUMAN; METASTASIS; OVARIECTOMY; POSTMENOPAUSE; PRACTICE GUIDELINE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPINAL CORD COMPRESSION; SYSTEMIC DISEASE; UNITED KINGDOM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DECISION MAKING; FEMALE; GOSERELIN; GREAT BRITAIN; HUMANS; OVARIECTOMY; PATIENT CARE TEAM; POSTMENOPAUSE; PREMENOPAUSE; RADIOTHERAPY; TAMOXIFEN;

EID: 84857924419     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2011.10.004     Document Type: Article

References (40)

1. National Institute for Health and Clinical Excellence. Advanced breast cancer: diagnosis and treatment. Clinical Guidelines CG81. Available at: . [accessed 16.07.10]. http://www.nice.org.uk/TA81.
2. National Institute for Health and Clinical Excellence. Improving outcomes in breast cancer-manual update. Available at: . [accessed 12.07.10]. http://www.mccn.nhs.uk/userfiles/documents/Improving_outcomes_breastcancer_manual.pdf.
3. Calman K, Hine D. A policy framework for commissioning cancer services: a report by the Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales. Available at: . [accessed 12.07.10]. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4071083.
4. Department of Health. Cancer Reform Strategy. Available at: . [accessed 12.07.10]. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_081006.
5. Secondary Breast Cancer Taskforce. Improving the care of people with metastatic breast cancer - final report. Available at: . [accessed 16.07.10]. http://www.breastcancercare.org.uk/upload/pdf/BCC_MainTaskforce_Report_AD3294_V5.pdf.
6. Eicher R.E.M., Marquard S., Aebi S. A nurse is a nurse? A systematic review of the effectiveness of specialised nursing in breast cancer. Eur J Cancer 2006, 42:3117-3127.
7. Amir E., Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?. Lancet Oncol 2009, 10(10):933-935.
8. Thompson A.M., Jordan L.B., Quinlan P., et al. Breast Recurrence in Tissues Study Group. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 2010, 12(6):R92.
9. Smith I.E., Dowsett M., Yap Y.S., et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006, 24(16):2444-2447.
10. Buzzoni R., Biganzoli L., Bajetta E., et al. Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology. Br J Cancer 1995, 71(5):1111-1114.
11. Gibson L., Lawrence D., Dawson C., Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009, (4):CD003370.
12. Iaffaioli R.V., Formato R., Tortoriello A., et al. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br J Cancer 2005, 92(9):1621-1625. Southern Italy Oncology Group.
13. Chia S., Gradishar W., Mauriac L., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008, 26(10):1664-1670.
14. Bertelli G., Garrone O., Merlano M., et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005, 69(6):471-477.
15. Thürlimann B., Hess D., Köberle D., et al. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004, 85(3):247-254.
16. Johnston S.J., Cheung K.L. Fulvestrant-a novel endocrine therapy for breast cancer. Curr Med Chem 2010, 17(10):902-914.
17. Dowsett M., Houghton J., Iden C., et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006, 17(5):818-826.
18. Kaufman B., Mackey J.R., Clemens M.R., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27(33):5529-5537.
19. Johnston S., Pippen J., Pivot X., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27(33):5538-5546.
20. Trudeau M.E., Clemons M.J., Provencher L., et al. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. J Clin Oncol 2009, 27(35):5906-5910.
21. O'Shaughnessy J., Osborne C., Pippen J., et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011, 364(3):205-214.
22. Audeh M.W., Carmichael J., Penson R.T., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376(9737):245-251.
23. von Minckwitz G., Schwenkglenks M., Skacel T., et al. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer 2008, 45(4):608-617.
24. Cardoso F., Bedard P.L., Winer E.P., et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009, 101(17):1174-1181. ESO-MBC Task Force.
25. von Minckwitz G., du Bois A., Schmidt M., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol 2009, 27(35):1999-2006.
26. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355(26):2733-2743.
27. Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28(7):1124-1130.
28. Gray R., Bhattacharya S., Bowden C., Miller K., Comis R.L. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009, 27(30):4966-4972.
29. Miles D.W., Chan A., Dirix L.Y., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28(20):3239-3247.
30. Robert N.J., Diéras V., Glaspy J., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29(10):1252-1260.
31. Fojo T., Wilkerson J. Bevacizumab and breast cancer: the E2100 outlier. Lancet Oncol 2010, 11(12):1117-1119.
32. O'Shaughnessy J., Miles D., Gray R.J., et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010, 28(15):1005.
33. Lutz S., Berk L., Chang E., et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011, 79(4):965-976. American Society for Radiation Oncology (ASTRO).
34. Sze W.M., Shelley M., Held I., Mason M. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systemic review of randomized trials. Clin Oncol 2003, 15(6):345-352.
35. Choi C.Y., Adler J.R., Gibbs I.C., et al. Stereotactic radiosurgery for treatment of spinal metastases recurring in close proximity to previously irradiated spinal cord. Int J Radiat Oncol Biol Phys 2010, 78(2):499-506.
36. Coleman R.E. Risks and benefits of bisphosphonates. Br J Cancer 2008, 98(11):1736-1740.
37. National Institute for Health and Clinical Excellence. Metastatic spinal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression. Available at: . [accessed 02.08.10]. http://www.nice.org.uk/nicemedia/live/12085/42653/42653.pdf.
38. Lee B., Franklin I., Lewis J.S., et al. The efficacy of percutaneous vertebroplasty for vertebral metastases associated with solid malignancies. Eur J Cancer 2009, 45(9):1597-1602.
39. Cole J.S., Patchell R.A. Metastatic epidural spinal cord compression. Lancet Neurol 2008, 7(5):459-466.
40. Ono M., Ando M., Yunokawa M., et al. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol 2009, 14(1):48-52.